PubRank

Vincent T Ho

Author PubWeight™ 90.65‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Interleukin-2 and regulatory T cells in graft-versus-host disease. N Engl J Med 2011 6.02
2 Cord colitis syndrome in cord-blood stem-cell transplantation. N Engl J Med 2011 3.83
3 ST2 as a marker for risk of therapy-resistant graft-versus-host disease and death. N Engl J Med 2013 3.27
4 Extended follow-up of methotrexate-free immunosuppression using sirolimus and tacrolimus in related and unrelated donor peripheral blood stem cell transplantation. Blood 2007 2.57
5 Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation. Blood 2007 2.54
6 Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease. Blood 2009 2.50
7 Improved survival in lymphoma patients receiving sirolimus for graft-versus-host disease prophylaxis after allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning. J Clin Oncol 2008 2.44
8 Long-term reduction in peripheral blood HIV type 1 reservoirs following reduced-intensity conditioning allogeneic stem cell transplantation. J Infect Dis 2013 2.17
9 Recovery of B-cell homeostasis after rituximab in chronic graft-versus-host disease. Blood 2010 2.17
10 Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: a randomized phase 2 trial from the Blood and Marrow Transplant Clinical Trials Network. Blood 2009 2.16
11 Immune reconstitution after double umbilical cord blood stem cell transplantation: comparison with unrelated peripheral blood stem cell transplantation. Biol Blood Marrow Transplant 2011 2.11
12 The impact of soluble tumor necrosis factor receptor etanercept on the treatment of idiopathic pneumonia syndrome after allogeneic hematopoietic stem cell transplantation. Blood 2008 2.09
13 Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease. Sci Transl Med 2013 2.03
14 Altered regulatory T cell homeostasis in patients with CD4+ lymphopenia following allogeneic hematopoietic stem cell transplantation. J Clin Invest 2010 2.00
15 A disease risk index for patients undergoing allogeneic stem cell transplantation. Blood 2012 2.00
16 Acute graft-versus-host disease biomarkers measured during therapy can predict treatment outcomes: a Blood and Marrow Transplant Clinical Trials Network study. Blood 2012 1.85
17 Impact of cytogenetics on outcome of de novo and therapy-related AML and MDS after allogeneic transplantation. Biol Blood Marrow Transplant 2007 1.84
18 Sirolimus, tacrolimus, and low-dose methotrexate for graft-versus-host disease prophylaxis in mismatched related donor or unrelated donor transplantation. Blood 2003 1.73
19 Prostaglandin-modulated umbilical cord blood hematopoietic stem cell transplantation. Blood 2013 1.72
20 Sirolimus is associated with veno-occlusive disease of the liver after myeloablative allogeneic stem cell transplantation. Blood 2008 1.71
21 Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: importance of histology for outcome. Biol Blood Marrow Transplant 2008 1.69
22 Bortezomib-based graft-versus-host disease prophylaxis in HLA-mismatched unrelated donor transplantation. J Clin Oncol 2012 1.68
23 Effect of up-front daclizumab when combined with steroids for the treatment of acute graft-versus-host disease: results of a randomized trial. Blood 2004 1.58
24 Allelic variations in CYP2B6 and CYP2C19 and survival of patients receiving cyclophosphamide prior to myeloablative hematopoietic stem cell transplantation. Am J Hematol 2010 1.54
25 Prospective cohort study comparing intravenous busulfan to total body irradiation in hematopoietic cell transplantation. Blood 2013 1.50
26 Sirolimus-based graft-versus-host disease prophylaxis protects against cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation: a cohort analysis. Blood 2007 1.44
27 Costs of allogeneic hematopoietic cell transplantation with high-dose regimens. Biol Blood Marrow Transplant 2008 1.41
28 Reduced-intensity conditioning hematopoietic stem cell transplantation in patients over 60 years: hematologic malignancy outcomes are not impaired in advanced age. Biol Blood Marrow Transplant 2010 1.39
29 Autologous CLL cell vaccination early after transplant induces leukemia-specific T cells. J Clin Invest 2013 1.30
30 Reduced-intensity conditioning stem cell transplantation: comparison of double umbilical cord blood and unrelated donor grafts. Biol Blood Marrow Transplant 2011 1.19
31 Obesity does not preclude safe and effective myeloablative hematopoietic cell transplantation (HCT) for acute myelogenous leukemia (AML) in adults. Biol Blood Marrow Transplant 2010 1.15
32 Rituximab prophylaxis prevents corticosteroid-requiring chronic GVHD after allogeneic peripheral blood stem cell transplantation: results of a phase 2 trial. Blood 2013 1.14
33 Hepatitis B virus reactivation following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2009 1.14
34 Iron overload in patients with acute leukemia or MDS undergoing myeloablative stem cell transplantation. Biol Blood Marrow Transplant 2010 1.13
35 Bortezomib, tacrolimus, and methotrexate for prophylaxis of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation from HLA-mismatched unrelated donors. Blood 2009 1.12
36 Cord-blood hematopoietic stem cell transplant confers an increased risk for human herpesvirus-6-associated acute limbic encephalitis: a cohort analysis. Biol Blood Marrow Transplant 2012 1.10
37 Novel approaches to the therapy of steroid-resistant acute graft-versus-host disease. Biol Blood Marrow Transplant 2004 1.09
38 Outcomes in patients age 70 or older undergoing allogeneic hematopoietic stem cell transplantation for hematologic malignancies. Biol Blood Marrow Transplant 2013 1.08
39 High-resolution HLA matching in double-umbilical-cord-blood reduced-intensity transplantation in adults. Transfusion 2009 1.06
40 Outcome and prognostic factors for patients who relapse after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2013 1.06
41 The impact of geographic proximity to transplant center on outcomes after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2011 1.06
42 A prognostic score for patients with acute leukemia or myelodysplastic syndromes undergoing allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2007 1.01
43 Does iron overload really matter in stem cell transplantation? Am J Hematol 2012 0.99
44 Busulfan dose intensity and outcomes in reduced-intensity allogeneic peripheral blood stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia. Biol Blood Marrow Transplant 2013 0.96
45 Seroprotective titers against 2009 H1N1 influenza A virus after vaccination in allogeneic hematopoietic stem cell transplantation recipients. Biol Blood Marrow Transplant 2010 0.92
46 Hyperlipidemia and statin use after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2011 0.90
47 Histologic features in colon biopsies can discriminate mycophenolate from GVHD-induced colitis. Am J Surg Pathol 2013 0.89
48 CNS relapse in acute promyeloctyic leukemia. J Clin Oncol 2010 0.88
49 Low telomerase activity in CD4+ regulatory T cells in patients with severe chronic GVHD after hematopoietic stem cell transplantation. Blood 2011 0.88
50 Comparison of T-cell-depleted and non-T-cell-depleted unrelated donor transplantation for hematologic diseases: clinical outcomes, quality of life, and costs. Blood 2002 0.86
51 Lymphocyte phenotype during therapy for acute graft-versus-host disease: a brief report from BMT-CTN 0302. Biol Blood Marrow Transplant 2012 0.84
52 Safety and efficacy of defibrotide for the treatment of severe hepatic veno-occlusive disease. Ther Adv Hematol 2012 0.84
53 Phase II trial of parathyroid hormone after double umbilical cord blood transplantation. Biol Blood Marrow Transplant 2012 0.83
54 Factors associated with bronchiolitis obliterans syndrome and chronic graft-versus-host disease after allogeneic hematopoietic cell transplantation. Am J Hematol 2014 0.81
55 Ex vivo T cell depletion of allogeneic PBSC as acute and chronic GVHD prophylaxis after myeloablative HCT: time to reconsider? Biol Blood Marrow Transplant 2011 0.81
56 Airway dilation in bronchiolitis obliterans after allogeneic hematopoietic stem cell transplantation. Respir Med 2012 0.81
57 White blood cell recovery after allogeneic hematopoietic cell transplantation predicts clinical outcome. Am J Hematol 2014 0.79
58 Invasive fungal disease after remote inoculation in transplant recipients. Clin Infect Dis 2011 0.79
59 Syngeneic donor hematopoietic stem cell transplantation is associated with high rates of engraftment syndrome. Biol Blood Marrow Transplant 2010 0.79
60 Phase I study of alemtuzumab for therapy of steroid-refractory chronic graft-versus-host disease. Biol Blood Marrow Transplant 2013 0.75
61 Peritoneal relapse of testicular seminomatous germ cell tumor treated successfully with salvage chemotherapy and autologous stem cell transplantation. Clin Genitourin Cancer 2011 0.75